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Symptomatic Presentation of Carotid Sinus Hypersensitivity
Is Associated With Impaired Cerebral Autoregulation
Maw Pin Tan, BMBS, MRCP, MD; Tom J. Chadwick, MA, PhD; Simon R. J. Kerr, MRCP, PhD; Steve W. Parry, MRCP, PhD
Background-—Carotid sinus hypersensitivity (CSH) is associated with syncope, unexplained falls, and drop attacks in older people
but occurs asymptomatically in 35% of community-dwelling elders. We hypothesized that impaired cerebral autoregulation is
associated with the conversion of asymptomatic CSH to symptomatic CSH. We therefore conducted a case–control study
evaluating individuals with CSH with and without the symptoms of syncope or unexplained falls, as well as non-CSH controls, to
determine whether the blood pressure and heart rate changes associated with CSH are associated with symptoms only when
cerebral autoregulation is altered.
Methods and Results-—Bilateral middle cerebral artery blood flow velocities (BFV) were measured in consecutive patients with
symptomatic CSH (n=22) and asymptomatic controls with (n=18) and without CSH (n=14) using transcranial Doppler
ultrasonography during lower body negative pressure-induced systemic hypotension. Within-group comparisons revealed
significantly lower cerebrovascular resistance index (CVRi) at nadir for the asymptomatic CSH group (right, mean [95% CI]: 2.2 [1.8,
2.8] versus 2.6 [2.2, 3.0]; P=0.005; left: 2.8 [2.4, 3.3] versus 3.1 [2.7, 3.8]; P=0.016). Between-group comparisons showed higher
mean BFV (right: estimated mean difference, B=5.49 [1.98, 8.80], P=0.003; left: 4.82 [1.52, 8.11], P=0.005) and lower CVRi (right:
B=0.08 [0.03, 0.12], P=0.003, left: B=0.07 [0.02, 0.12], P=0.006) in asymptomatic CSH versus symptomatic CSH groups. There
were no significant differences in bilateral mean BFV or right CVRi between the non-CSH and symptomatic CSH groups but
differences were present for left CVRi (B=0.07 [0.02, 0.013], P=0.015).
Conclusion-—Cerebral autoregulation is altered in symptomatic CSH and therefore appears to be associated with the development
of hypotension-related symptoms in individuals with CSH. ( J Am Heart Assoc. 2014;3:e000514 doi: 10.1161/JAHA.
113.000514)
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C arotid sinus hypersensitivity (CSH) is characterized by anasystolic or hypotensive response to carotid sinus
massage (CSM) and is associated with syncope, unexplained
falls, and drop attacks in older individuals.1–3 CSH is rare
before the age of 40 years, but is diagnosed with increasing
frequency with advancing age.4 Prodromal symptoms are
absent in up to 93% of patients with carotid sinus syncope,
and high serious injury rates have been reported, with 25%
of patients sustaining fractures.5
The diagnostic yield of CSM in individuals with unexplained
syncope or falls has been reported as 14% to 54% by various
groups with varying case selection and methods of investiga-
tion.4,6,7 However, a community study has found that CSH was
also present in 35% of community-dwelling older individuals
without any symptoms of syncope, falls or drop attacks.8 This
high prevalence of CSH in asymptomatic older individuals
raises the question of the validity of a pathological role for CSH,
particularly given recent data showing no benefit for pacing
intervention in patients with CSH associated with unexplained
falls9,10 and further data questioning the causal role of CSH in
syncope, falls, and drop attacks.11 In contrast, CSH associated
with syncope is a Class I indication for permanent pacing,12,13
albeit with largely observational data and consensus support-
ing these recommendations.14,15 Furthermore, real-time
recording of patients with CSH using implantable loop
recorders shows asystole during characteristic symptoms.16
A recent study reporting the association between hypotension
during head turning with the presence of CSH further adds
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validity to the pathological role of CSH. In addition, the authors
observed a discrepancy between head-turning–induced
hypotension and the presence of symptoms.17 It is possible,
therefore, that additional pathological factors exist that result
in the conversion of individuals with asymptomatic CSH to
symptomatic CSH (often labeled “carotid sinus syndrome” but
termed symptomatic CSH here to avoid confusion).
We hypothesized that impaired cerebral autoregulation is
one such converting factor and have previously shown altered
cerebral autoregulation as measured by using transcranial
Doppler ultrasonography (TCD) in patients with symptomatic
CSH and controls whose CSH status was unknown.18 In order
to test this hypothesis more rigorously, we assessed cerebral
autoregulation during controlled systemic hypotension induced
by lower body negative pressure in individuals with symptom-
atic and asymptomatic CSH and in controls without CSH.
Methods
Consecutive patients with symptomatic CSH diagnosed follow-
ing investigation with CSM for syncope, unexplained falls, and
drop attacks at our specialist syncope facility were invited to
participate in our study. Asymptomatic older people aged
>65 years were recruited from an existing community-dwelling
cohort investigated with CSM.8 This latter group therefore
composed 2 groups of individuals without any history of
syncope, unexplained falls, or drop attacks: an asymptomatic
CSH group and an asymptomatic control group without CSH.
Carotid sinus massage was conducted using established
protocols19 with 5 to 10 seconds of bilateral, sequential CSM
conducted at the point of maximal pulsation of the carotid
arteries, right sided then left, in the supine position followed by
70° head-up tilt position.19,20 Continuous ECG and beat-to-
beat blood pressure (Taskforce; CNSystems) were recorded
throughout. Carotid sinus hypersensitivity was defined as
asystole of ≥3 seconds and/or systolic blood pressure (SBP)
reduction of ≥50 mm Hg in response to CSM. Symptomatic
CSH was defined as the presence of symptoms of syncope,
falls, or drop attacks with a positive CSM. Potential participants
were excluded if they had a permanent cardiac pacemaker or if
they were unable to provide informed consent. Carotid Doppler
ultrasound studies were conducted on all participants to rule
out significant internal carotid artery stenosis, which can affect
cerebral blood flow velocity measurements. The study was
approved by the local research ethics committee, and all
participants provided written informed consent.
Transcranial Doppler Ultrasound
Bilateral middle cerebral artery (MCA) blood flow velocities
were measured continuously using TCD (Digilite; RIMED).
The MCAs were insonated using 2-MHz TCD probes through
the transtemporal windows, which were then fixed in
position using a specially designed head gear. The TCD
signals were then synchronized to beat-to-beat blood
pressure measurements (Taskforce; CNSystems). End-tidal
CO2 was also recorded simultaneously using a nasal or
oronasal cannula and infrared capnography (Oxi-pulse
Capnograph System; SIMS-BCI) to monitor for hypocapnea
with its potential to cause intracerebral arterial vasocon-
striction.21
Lower Body Negative Pressure
We used graded lower body negative pressure (LBNP) to
induce a controlled fall in SBP mimicking the reductions in
SBP that would occur spontaneously in CSH. Cerebral
autoregulation cannot be maintained below a critical SBP of
around 50 mm Hg in most individuals.22 Hence, real-time
CSM-induced CSH would provide an inaccurate and mislead-
ing view of cerebral autoregulation in patients with CSH. In
addition, comparable levels of blood pressure reduction
cannot be achieved with CSM in individuals without CSH,
because non-CSH individuals will have a smaller hypotensive
response to CSM. Graded LBNP therefore allows us to
compare the cerebral blood flow velocity between CSH and
non-CSH individuals in response to an identical hypotensive
insult.
Participants were asked to assume the supine position in a
temperature-controlled, dimly lit, quiet room for 15 minutes
prior to the procedure. A custom-built LBNP chamber was
used to induce LBNP suction at 20 mm Hg for 8 minutes,
followed by 40 mm Hg for an additional 8 minutes. The
target reduction in SBP was 50 mm Hg from maximal
recorded SBP and/or a 50% fall from maximal SBP. Lower
body suction was discontinued as soon as the target SBP
drop was achieved and/or hypotensive symptoms
supervened.
Assessment of Cerebral Autoregulation
TCD has been used extensively in the assessment of cerebral
autoregulation.18,21,23,24 While this complex process cannot
be directly assessed by using current technology, TCD
measures of changes in cerebral arterial blood flow velocities
provide an accurate surrogate measure of cerebral autore-
gulation. Systolic (SBFV), diastolic (DBFV), and mean (MBFV)
cerebral blood flow velocities were determined at baseline
and at SBP nadir. MBFV was determined by calculating the
true mean within the spectral envelope. Baseline values were
obtained by calculating the mean SBFV, DBFV, and MBFV for
20 beats immediately before the commencement of LBNP.
Nadir was defined as the point at which SBP was lowest
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during LBNP. The minimal SBFV, DBFV, and MBFV around
this point were recorded. As the TCD signals were synchro-
nized to continuous blood pressure measurements, corre-
sponding values were obtainable for SBP, diastolic blood
pressure, and mean arterial pressure (MAP) at baseline and
nadir.
The cerebrovascular resistivity index (CVRi) was then
calculated for baseline and nadir by dividing the cerebral
perfusion pressure (CPP) by the MBFV (CVRi=CPP/MBFV).
Cerebral perfusion pressure is assumed to approximate to
MAP as intracranial pressure is considered negligible in our
subjects who were assessed in the supine position. The CVRi
is a measure of the interrelationship between cerebral
perfusion pressure and cerebral blood flow. In the absence
of cerebral autoregulation, CVRi will remain constant as
cerebral blood flow changes commensurate with changes in
CPP. Appropriate changes in CVRi in response to alterations in
CPP therefore indicate the presence of intact cerebral
autoregulation.
Data Analysis
All data analyses were conducted with the use of anonymized
data. Continuous variables were plotted as histograms and
assessed by using the Komolgorov–Smirnov test to determine
normal distributions. The CVRi was non-normally distributed,
and, hence, its inverted value cerebrovascular conductance
(CVCi=MBFV/CPP) was used for statistical analysis. The
baseline characteristics of the 3 study groups were first
compared with the use of ANOVA for continuous variables
or v2 test for categorical variables to identify baseline
differences between groups. Within-group comparisons for
SBFV, MBFV, DBFV, and CVRi for bilateral TCD measurements
at baseline and nadir were then carried out with paired
t tests.
Subsequent between-group analyses involved only 2
preplanned comparisons between the symptomatic CSH
and asymptomatic CSH groups and the symptomatic CSH
and non-CSH control groups. Linear regression methods
were used to compare the values of MBFV and CVRi at
nadir using entry method for potential confounding vari-
ables to control for differences in baseline MBFV, baseline
CPP, and nadir CPP. Adjustments for age and sex were
considered, but it was decided to limit the covariates that
were adjusted for due to the small sample size. All
statistical analyses were conducted using the SPSS 15.0
statistical software package. A planned comparison based
on 20 per group between, for example, the symptomatic
versus asymptomatic group using the 2-sample t test would
result in 80% power to detect an effect size of 0.9 (for any
comparison between 2 groups on a continuous outcome
measure).
Results
Baseline Characteristics
Fifty-four participants were recruited to the study: 22 in the
symptomatic CSH group, 18 in the asymptomatic CSH group,
and 14 in the non-CSH control group. The baseline charac-
teristics of each group are summarized in Table 1. There were
no significant differences in any of the baseline demographics,
medical history, medications, and hemodynamic indices
Table 1. Baseline Characteristics of Participants
Characteristics
Symptomatic
CSH (n=22)
Asymptomatic
CSH (n=18)
No CSH
(n=14)
Age (y), mean (SE) 73.0 (2.0) 77.7 (2.1) 76.6 (1.3)
Male sex, n (%) 11 (50) 14 (78) 8 (57)
Cardioinhibitory subtypes 8 (36) 9 (50)
ΔSBP <50 mm Hg 4 (18) 1 (6)
ΔSBP ≥50 mm Hg 4 (18) 8 (44)
Vasodepressor subtype 14 (64) 9 (50)
Medical history, n (%)
Arthritis 6 (27) 9 (50) 8 (57)
Asthma/COPD 3 (14) 3 (17) 3 (21)
Hypertension 9 (41) 9 (50) 5 (36)
Angina 5 (23) 5 (28) 4 (29)
Myocardial infarction 2 (9) 4 (22) 4 (29)
Medications, n (%)
Antiplatelets or
anticoagulants
13 (59) 6 (33) 5 (36)
b-Adrenoceptor
antagonists
2 (9) 2 (11) 5 (26)
ACE inhibitors 7 (32) 1 (6) 4 (29)
Angiotensin II
antagonists
2 (9) 2 (11) 1 (7)
Calcium channel
antagonist
5 (23) 6 (33) 4 (29)
Diuretics 6 (27) 4 (22) 3 (21)
Lipid-lowering drugs 13 (59) 4 (22) 4 (29)
Proton pump inhibitors 5 (23) 3 (17) 2 (14)
Baseline heart rate, bpm†‡ 72 (2) 62 (2) 63 (4)
Baseline SBP, mm Hg† 124 (2) 133 (4) 131 (17)
Baseline DBP, mm Hg† 78 (3) 80 (3) 77 (5)
Baseline CPP, mm Hg† 90 (2) 95 (3) 95 (5)
Baseline end-tidal CO2,
kPa†
4.5 (0.2) 4.6 (0.1) 4.3 (0.3)
ACE indicates angiotensin-converting enzyme; bpm, beats per minute; CPP, cerebral
perfusion pressure; COPD, chronic obstructive pulmonary disease; CSH, carotid sinus
hypersensitivity; DBP, diastolic blood pressure; SBP, systolic blood pressure. †During
10 minutes’ supine rest, ‡P<0.05.
DOI: 10.1161/JAHA.113.000514 Journal of the American Heart Association 3
Cerebral Autoregulation in Symptomatic CSH Tan et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at Newcastle University on September 24, 2014http://jaha.ahajournals.org/Downloaded from 
between the 3 groups apart from the use of lipid-lowering
medications and resting heart rate. End-tidal CO2 levels
between the 3 groups were not significantly different at both
baseline and nadir (Tables 1 and 2). Five subjects did not have
adequate transtemporal windows from which to obtain
meaningful cerebral blood flow measurements and were
excluded from subsequent analyses. Only right-sided mea-
surements were available from 2 subjects and only left-sided
measurements were available from 2 subjects. There were no
significant differences in MAP at SBP nadir and maximal
reduction in SBP between the 3 groups (Table 2).
Within-Group Comparisons
The Figure demonstrates the relationship between in MAP and
MBFV in an individual with symptomatic CSH and impaired
cerebral autoregulation. Paired comparisons were conducted
between baseline and nadir cerebral blood flow values
(Table 3). The SBFV, DBFV, and MBFV at the right MCA was
significantly lower at nadir compared with baseline for all 3
groups, suggesting that reductions in CBFV are observed with
reductions in blood pressure. CVCi rather than CVRi was
calculated to obtain a normal distribution. CVRi was not
significantly different between baseline and nadir for the right
MCA for both the symptomatic CSH group and the non-CSH
control group. No change in CVR in response to changes in
CPP suggests that cerebral autoregulation is impaired. The
asymptomatic CSH group, however, had significantly lower
CVRi at nadir compared with baseline at the right MCA,
indicating the presence of appropriate and intact cerebral
autoregulation. The left MCA also demonstrated significant
reductions in SBFV, DBFV, and MBFV between baseline and
nadir in all 3 groups. Similarly, CVRi was not significantly
different between baseline and nadir for the left MCA for the
symptomatic CSH or the non-CSH control group, while the
asymptomatic CSH group, however, had significantly lower
CVRi at nadir compared with baseline in the left MCA
measurements.
Mean Blood Flow Velocity
For right MCA measurements, using linear regression to
adjust for potential confounders, MBFV was significantly
lower in the symptomatic CSH group compared with the
asymptomatic CSH group (P<0.05), with no significant
differences in MBFV between the symptomatic CSH group
and the non-CSH control group. For the left side, however,
MBFV remained significantly lower in the symptomatic CSH
group compared with the asymptomatic CSH group
(P<0.01), however, the MBFV between the symptomatic
CSS group and the non-CSH control group approached
borderline significance (P=0.088) (Table 4).
Table 2. Hemodynamic, Carotid Doppler Flow, and End-Tidal
CO2 Characteristics at Nadir*
Characteristics
Symptomatic
CSH (n=22)
Asymptomatic
CSH (n=17)
Non-CSH
Controls
(n=10) P Value†
Nadir CPP,
mm Hg,
mean (SE)
72 (2) 73 (2) 75 (5) 0.841
Nadir end-tidal
CO2, kPa,
mean (SE)
4.6 (0.1) 4.8 (0.2) 4.4
(0.2)
0.439
Maximal ΔSBP,
mm Hg,
mean (SE)
50 (2) 51 (2) 41 (4) 0.067
CPP indicates cerebral perfusion pressure; CSH, carotid sinus hypersensitivity;
SBP, systolic blood pressure.
*Nadir is defined as the point of the minimal SBP during lower body negative pressure.
†ANOVA.
Table 3. Differences Between Cerebral Blood Flow Velocities
and Cerebrovascular Resistance at Baseline and Nadir
Characteristics,
Mean Difference
(SE)
Symptomatic
CSH
Asymptomatic
CSH
Non-CSH
Controls
Right MCA n=21 n=17 n=9
SBFV, cm/s 15.17 (2.05) 11.38 (3.05) 10.29 (3.84)
P value* <0.001|| 0.002§ 0.028‡
DBFV, cm/s 7.39 (1.51) 3.41 (1.03) 6.49 (1.22)
P value* <0.001|| 0.005§ 0.001§
MBFV, cm/s 8.88 (1.47) 4.75 (1.52) 6.33 (2.37)
P value* <0.001|| 0.007§ 0.028‡
CVCi
†, cm/s
per mm Hg
0.038 (0.017) 0.060 (0.018) 0.014 (0.026)
P value* 0.121 0.005§ 0.629
Left MCA n=19 n=17 n=10
SBFV, cm/s 14.01 (1.86) 8.12 (1.40) 8.97 (2.57)
P value* <0.001|| <0.001|| 0.007§
DBFV, cm/s 7.60 (1.40) 5.28 (1.11) 2.07 (1.33)
P valuea <0.001|| <0.001|| 0.156
MBFV, cm/s 8.12 (1.23) 3.36 (1.25) 4.35 (1.01)
P valuea <0.001|| 0.016‡ 0.002§
CVCi,
† cm/s
per mm Hg
0.037 (0.019) 0.043 (0.017) 0.033 (0.029)
P value* 0.060 0.025‡ 0.288
CSH indicates carotid sinus hypersensitivity; CVCi, cerebrovascular conductance index;
DBFV, diastolic blood flow velocity; MBFV, mean blood flow velocity; MCA, middle
cerebral artery; SBFV, systolic blood flow velocity.
*Paired t tests.
†Derived from the inverse value of CVRi (CVCi=1/CVRi).
‡P<0.05, §P<0.01, ||P<0.001.
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Cerebrovascular Resistive Index
The CVRi at nadir for both right-side and left-sided
measurements were significantly higher in the symptomatic
CSH group compared with the asymptomatic CSH group
(P<0.05). There was no significant difference between the
symptomatic CSH group and the non-CSH controls for
the right MCA, but the differences between the 2 groups
Figure. Mean arterial pressure and cerebral blood flow in response to lower body negative pressure. This
is a time-series plot demonstrating the relationship between mean arterial pressure (MAP) and cerebral
blood flow velocity (MBFV) in an individual with symptomatic carotid sinus syndrome. A marked reduction in
MAP was observed with lower body negative pressure, with typical sinusoidal fluctuations over time.
Cerebral blood flow velocity should remain relatively constant in response to changes in MAP but fluctuated
with MAP, and fell rapidly with the fall in MAP in response to lower body negative pressure. This suggests
marked impairment in cerebral autoregulation. CPP indicates cerebral perfusion pressure; LBNP, lower body
negative pressure.
Table 4. Linear Regression Analysis for Mean Cerebral Blood Flow and Reciprocal of Cerebrovascular Resistance at Nadir
Non-CSH Controls vs Symptomatic CSH Asymptomatic CSH vs Symptomatic CSH
B (95% CI) P Value B (95% CI) P Value
Right middle cerebral artery
Mean cerebral blood flow velocity,* cm/s 0.749 (5.40 to 3.90) 0.747 4.07 (0.34 to 7.80) 0.033§
Cerebrovascular conductance,†,‡ cm/s per mm Hg 0.011 (0.05 to 0.08) 0.737 0.08 (0.03 to 0.14) 0.003||
Left middle cerebral artery
Mean cerebral blood flow velocity,* cm/s 3.35 (0.17 to 7.31) 0.088 4.49 (1.52 to 8.11) 0.009||
Cerebrovascular conductance,†,‡ cm/s per mm Hg 0.06 (0.02 to 0.15) 0.043§ 0.06 (0.01 to 0.11) 0.026||
B indicates parameter estimate (represents the estimated mean difference between groups); CSH, carotid sinus hypersensitivity.
*Linear regression adjusted for baseline cerebral perfusion pressure (CPP), nadir CPP, baseline mean cerebral blood flow velocity.
†Adjusted for baseline CPP, nadir CPP, cerebrovascular conductance at baseline.
‡Cerebrovascular conductance=1/cerebrovascular resistance.
§P<0.05, ||P<0.01.
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achieved statistical significance for the left MCA (P=0.043)
(Table 4).
Discussion
Cerebral autoregulation is a complex mechanism through
which intracranial blood flow is maintained in response to
variations in systemic blood pressure. This process is
influenced by various metabolic factors as well as the
autonomic nervous system. For many years, scientists have
reported that cerebral blood flow remains constant within an
“autoregulatory range,” as demonstrated by experiments
using xenon diffusion methods.25 However, with the advent
of TCD, cerebral blood flow can now be assessed in real time
with every heartbeat.26 It has since become apparent that
cerebral blood flow does fluctuate alongside fluctuations in
systemic blood pressure, and cerebral autoregulation
appears to “buffer” the changes in cerebral blood flow
leading to a lower coherence between MAP and cerebral
blood flow.
Our study has demonstrated that individuals with symp-
tomatic CSH have lower cerebral blood flow than do
asymptomatic individuals with CSH in response to compara-
ble reductions in systemic blood pressure. This suggests that
symptomatic individuals have an increased susceptibility to
syncope or falls compared with individuals with asymptomatic
CSH due to a lower ability to maintain cerebral blood flow in
the face of a hypotensive challenge. The derived measure of
CVRi takes into account changes in MAP as well as cerebral
blood flow. Cerebral autoregulation is therefore intact if a
reduction in CVRi is observed in response to a reduction in
MAP. This was the case for the asymptomatic CSH group in
our study in the within-group comparisons, in contrast to no
changes in CVRi from baseline to nadir in the symptomatic
group.
There was no significant difference in CVRi between the
symptomatic CSH group and the non-CSH control group. This
may indicate that cerebral autoregulation may also be
impaired in our control group without CSH. The asymptomatic
groups of community-dwelling older individuals were not
necessarily healthy controls but were individuals without the
symptoms of syncope, falls, or drop attacks. These individuals
remain spared of symptoms of syncope or recurrent falls in
the absence of the heart rate or blood pressure abnormalities
observed in individuals with CSH. There were borderline
significant differences in MBFV and CVRi in the left, dominant
hemisphere but no differences in MBFV in the right,
nondominant hemisphere between the symptomatic CSH
group and the non-CSH control group. While the symptomatic
CSH and non-CSH control groups may be due to a type II
error, it also supports the theoretical supposition that the lack
of statistical significance has been confounded by the
presence of impaired cerebral autoregulation in some of
the individuals in the non-CSH control group. In addition, the
difference between right and left also raises the concept of
differential cerebral autoregulatory capacity between the
2 cerebral hemispheres, with protective relative sparing of
the dominant hemisphere in the non-CSH control group,
which will be an interesting topic for future studies.
Cerebral autoregulation in CSH had been evaluated in
3 previous small studies. Lefteriotis et al27,28 measured
cerebral blood flow in patients with cardioinhibitory CSH in
2 similar studies during CSM with OOO and DDD pacing in
9 and 11 individuals, respectively. The authors drew the
conclusion that cerebral autoregulation was preserved in
individuals with CSH through an estimation of the lower limit
of autoregulation and rate of recovery of cerebral blood flow
without comparisons with a control group. They had, however,
documented large increases in cerebrovascular resistance
following CSM with no pacing (OOO), but attributed this to the
CPP dropping below the lower limit of autoregulation.27,29 A
subsequent study by our group suggested that cerebral
autoregulation is impaired in symptomatic CSH18 through the
observation of an overall reduction in cerebral blood flow
velocity and increase in cerebrovascular resistance in sub-
jects with symptomatic CSH compared with healthy older
controls whose CSH status was unknown. These previous
studies had not considered individuals with asymptomatic
CSH.
This potential mechanism for impaired cerebral autoregu-
lation was not evaluated in this study. The complex
mechanisms underlying cerebral autoregulation remain
poorly understood. Cerebral blood flow is said to remain
constant at around 60 mL/100 g per minute through a wide
range of blood pressure. This is achieved through cerebral
blood flow self-regulation (cerebral autoregulation), which is
controlled by local metabolic factors that include myogenic
responses to transmural pressure,30 nitric oxide,31 CO2,
32 H+
concentrations, potassium, adenosine, and calcitonin gene–
related peptide.33 Factors such as hypocapnia are known to
stimulate cerebral vasoconstriction and have been found to
contribute to the reduction in cerebral blood flow seen
experimentally in subjects with orthostatic intolerance and
neurally mediated syncope.21,32 However, there was no
significant difference in end-tidal CO2 among the 3 groups in
our study, suggesting that hypocapnia does not explain the
reduction in cerebral blood flow during induced hypotension
in individuals with symptomatic CSH. Because impaired
cerebral autoregulation is only present in the symptomatic
CSH group, the mechanism for impaired cerebral autoregu-
lation is likely to differ from the underlying mechanisms
for CSH, which has been shown to be associated with
resting sympathetic overactivity and increased baroreflex
sensitivity.34
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Limitations
The ability to perform TCD studies is reliant on the availability
of an adequate bone window, because ultrasound conducts
poorly through bone, which is not possible in up to 10% of
subjects.35 In addition, several assumptions are made in the
estimation of cerebral blood flow velocity. First, laminar flow
exists in the center of the vessels, as velocity changes out of
proportion to flow in the unlikely situation of nonlaminar
flow.36 Second, the angle of insonation and the diameter of
the blood vessels remain constant. The large cerebral arteries
are capacitance rather than resistance vessels, and hence
changes in arterial pressure should have negligible effects on
vessel diameter. This assumption has been substantiated by
direct observations during craniotomy,37 magnetic resonance
imaging during orthostatic stress simulated by LBNP, and
xenon clearance studies.38,39 The magnitude of SBP reduction
in the non-CSH group was smaller than the 2 CSH groups, but
this observed difference was not statistically significant. Only
30% of non-CSH participants achieved the target SBP drop of
>50 mm Hg compared with 67% of CSH participants, as the
CSH and non-CSH participants appeared to have different
hemodynamic response patterns to LBNP. However, similar
MAP at nadir was achieved for all 3 groups, and BP changes
achieved in the symptomatic and asymptomatic groups were
similar. These potential differences were also adjusted for
statistically. The significant difference in MBFV and CVRi was
noted between the 2 CSH groups, but not between non-CSH
controls and the symptomatic CSH group. The statistical
power of this study is also limited by its small sample size,
which was unavoidable due to the specific nature of its
recruitment criteria.
Implications of the Study
Our results show a clear association between impaired
cerebral autoregulation and the symptomatic presentation of
CSH. Normal cerebral autoregulation in the asymptomatic
CSH group provides further evidence that it is the abnormality
in cerebral autoregulation that is the proximate cause of
syncope, unexplained falls, and drop attacks associated with
CSH rather than the hypersensitive response per se. This may
help explain why there is so little in the literature regarding
the pathophysiology of CSH, with the only tested hypothesis
to date, that of central a-adrenoceptor upregulation,40 failing
to withstand experimental scrutiny.41 There is increasing
evidence that CSH is associated with autonomic dysfunction,
with neuropathological studies showing increased neurode-
generative substrates within key medullary autonomic
nuclei42 and physiological studies demonstrating sympathetic
hyporesponsiveness4,43,44 in individuals with symptomatic
CSH. The role of the autonomic nervous system in the
regulation of cerebral blood flow has previously been
described,45 and our results provide further circumstantial
evidence suggesting that symptomatic CSH is the ultimate
expression of a more generalized autonomic disorder. This
has important implications for potential therapies in symp-
tomatic CSH; permanent pacing appears to be effective in the
cardioinhibitory subtype associated with syncope, but va-
sodepressor CSH has no specific therapy. Our work suggests
that less invasive measures could help ameliorate the
disorder, with important implications for future pathophysio-
logical, prevention, and treatment studies.
Conclusion
Cerebral blood flow is lower during LBNP in patients with
symptomatic CSH than in asymptomatic older individuals with
CSH, with corresponding increases in CVRi, indicating that the
symptomatic presentation of CSH is associated with impaired
cerebral autoregulation. These clear differences in MBFV and
CVRi were, however, not observed between the non-CSH
control and symptomatic CSH groups. Non-CSH controls
remain asymptomatic in the absence of CSH, while CSH
controls remain asymptomatic in the absence of altered
cerebral autoregulation. Autonomic dysfunction may be the
ultimate site of the pathological underpinning of symptomatic
CSH, providing an important target for further explanatory and
therapeutic studies.
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